Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
(WorldNews Health)

19.10.2018 23:58:03 CET FDA approves asthma indication for Dupixent® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent asthma, regardless of phenotype Only asthma biologic that offers patient self-administration at home Only asthma biologic also approved for adult patients with moderate-to-severe atopic dermatitis, a Type 2 inflammatory disease driven by the IL-4 and IL-13 pathway In clinical trials, Dupixent reduced severe exacerbations and oral corticosteroid use and improved lung function PARIS and TARRYTOWN, NY - October 19, 2018 - The U.S. Food and Drug Administration has...